Enjoy complimentary customisation on priority with our Enterprise License!
The global autoimmune disease diagnostics market size is estimated to grow by USD 2.99 billion at a CAGR of 9.59% between 2023 and 2028.
The increasing number of consolidations within the market allows technology exchange, leading to the development of robust immunoassay systems. The autoimmune disease diagnostics market has been witnessing a number of industrial consolidations. The major emphasis for such consolidations can be partly attributed to the manufacturers' intention to expand their portfolio and to incorporate and integrate technology with existing platforms and assays. As a part of such consolidations, manufacturers engage in technology sharing that has led to the introduction of many successful, robust automated immunoassay platforms, which are becoming a trend for manufacturers to attract a wide customer base. Therefore, the increase in the M&A is driving the growth of the global autoimmune disease diagnostics market during the forecast period.
Technavio has segmented the market into Type, Product and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 - 2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the localized autoimmune disease diagnostics segment will be significant during the forecast period. The growing incidence of localized autoimmune diseases such as type 1 diabetes, autoimmune thyroiditis, celiac disease, Inflammatory Bowel Diseases(IBD), and primary biliary cirrhosis is expected to propel the market growth.
Get a glance at the market contribution of various segments Download PDF Sample
The localized autoimmune disease diagnostics segment was the largest and was valued at USD 2.14 billion in 2018. Localized autoimmune response against a particular organ leads to organ-specific autoimmune disorders. The auto-antibodies act against their own organs by binding with self-antigens to suppress organ function or cause overstimulation of cells. Further, the growing demand for home care test kits is expected to fuel the growth of the localized autoimmune disease diagnostics market. For example, IBDoc, made by BUHLMANN, helps measure faecal inflammation marker calprotectin at home. This represents continuous advancements in personalized medicine. With such home care test kits, individuals can self-test IBDs such as Crohn's disease and ulcerative colitis. This will drive the adoption rates of localized autoimmune diagnostic tests as it expands the scope into new applications (home care). In addition, collaboration activities between pharmaceutical companies and diagnostic companies are expected to bring novel diagnostic tests into the market.
Assay kits are generally used in life science research, environmental monitoring, and drug discovery and development applications. These kits provide reagents that are required to perform analytical tests for the measurement of specific analytes used for different applications in analytical laboratories, biotechnology, and medical research. The increasing adoption of assay kits for autoimmune disease diagnostics drives the demand in the assay kits segment. Factors like the growing need for diagnostics testing for various autoimmune diseases, such as diabetes and others and the increasing demand for point-of-care (PoC) testing will propel the growth of the assay kits segment. Therefore, the assay kits segment of the global autoimmune disease diagnostics market is expected to grow during the forecast period.
An analyzer is a medical laboratory instrument that is designed to measure different chemicals and other analytes in different biological samples with minimal human assistance without taking too much time. Clinical chemistry analyzers run assays on various clinical samples, including blood, serum, plasma, urine, and cerebrospinal fluid, in order to detect the presence of analytes that are associated with specific diseases or drugs. These analyzers add great value in evaluating patients with suspected autoimmune diseases. The results from the analyzer help in confirming a diagnosis of autoimmune disorder, besides estimating disease severity and aiding in assessing the prognosis. Therefore, the increasing prevalence of autoimmune diseases across the world will propel the growth of the analyzer segment of the global autoimmune disease diagnostics market during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The growing incidence of autoimmune disorders, such as RA, SLE, and IBD, is expected to fuel the market growth in the Americas. For instance, according to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease affects more than 50 million US people annually. It is one of the top ten reasons for death in women of age less than 65 years and is the second-leading cause of chronic illness in the US. Also, an autoimmune disease in the US is a poorly understood category of disease comparable to heart disease and cancer. Therefore, researchers are continuously focusing on the development of novel diagnostic products to improve patient outcomes. Such initiatives will lead to an improved understanding of the disease, wherein medications can be administered based on individual needs. This represents a huge step toward the advancement of precision medicine.
In addition, factors such as the increasing prevalence of autoimmune diseases and the prevalence of rheumatoid arthritis among the rising ageing population in the US are attributed to the increasing market size of North America. For instance, according to the CDC, in the US, 24% of all adults, or 58.5 million people, had arthritis in 2021. Therefore, such factors will propel the growth of the autoimmune disease diagnostics market in the region during the forecast period.
The outbreak of the COVID-19 pandemic in 2020 severely impacted the growth of the autoimmune disease diagnostics market in North America. However, with the help of widespread COVID-19 vaccination programs, the number of COVID-19 cases declined to some extent by the first half of 2021, which stabilized the growth of the regional market in focus following the restoration of supply chain activities. Moreover, the rescheduling of patient visits to clinics and hospitals and the increased adoption of autoimmune disease diagnostics are expected to boost the growth of the regional autoimmune disease diagnostics market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Bio Rad Laboratories Inc. - The company offers autoimmune diagnostics solutions such as BioPlex 2200 Autoimmune Panels.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Advancements in laboratory automation platforms are notably driving market growth. The incidence of autoimmune diseases is rising worldwide, which is increasing the volume of samples being collected for analysis. This has led to the demand for automation in autoimmune disease diagnostics for rapid analysis and interpretation of results. Automation involves a series of integrated steps that include pre-analytical and post-analytical stages to help minimize the need for manual intervention and thus avoid errors. Most central laboratories resort to the use of automation as they conduct large-scale analyses of samples. Companies are offering automated systems to central and medium-sized laboratories for sample analysis.
However, decentralized testing for autoimmune disease diagnosis is gaining popularity among medical facilities. This procedure reduces the time required for sending the sample for analysis from the central laboratories. However, the limited understanding of autoimmune diseases and the need for confirmatory results for effective therapy are resulting in the need for centralized testing of samples for disease diagnosis. Therefore, such factors drive the growth of the global autoimmune disease diagnostics market during the forecast period.
Focus on companion diagnostic tests is an emerging trend shaping the market growth. Companion diagnostics allow the screening of individuals or groups who are likely to respond better to a therapeutic agent. The advances in companion diagnostic test for an autoimmune disease involves the use of a diagnostic test and monitoring of disease prognosis in individuals undergoing therapy.
In addition, the test offers insights into the therapeutic regimen's positive impact on these people by reducing the intensity of autoimmune diseases. Therefore, the growing focus on companion diagnostic tests will drive the growth of the global autoimmune disease diagnostics market during the forecast period.
Significant concerns over the lack of standardization in the quality of immunoassay kits is a significant challenge hindering the market growth. Accuracy and consistency are the major factors that influence the quality of diagnostic tests. From a laboratory technician's perspective, there are marked variations in the quality of results obtained from many commercialized immunoassay kits. This is evident primarily in the diagnosis of systemic vasculitis using ANCA testing. For instance, granulomatosis with polyangiitis can be life-threatening when the disease is not diagnosed quickly and accurately.
However, there is a large range of varied performance characteristics for immunoassay tests across various laboratories in the world, particularly in Europe. Such inconsistencies pose a serious challenge to diagnosis and treatment and will affect the brand equity of the manufacturers. Therefore, such factors will adversely impact the growth of the global autoimmune disease diagnostics market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Autoimmune Disease Diagnostics Market Customer Landscape
The autoimmune disease diagnostics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
|
Autoimmune Disease Diagnostics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
162 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.59% |
|
Market Growth 2024-2028 |
USD 2.99 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.85 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 42% |
|
Key countries |
US, Canada, UK, Germany, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Autoimmune Technologies LLC, Bio Rad Laboratories Inc., bioMerieux SA, Danaher Corp., DiaSorin SpA, Exagen Inc., F. Hoffmann La Roche Ltd., Gold Standard Diagnostics Corp., Grifols SA, Hemagen Diagnostics Inc., HUMAN Gesellschaft fur Biochemica und Diagnostica mbH, Immco Diagnostics Inc., Laboratory Corp. of America Holdings, PerkinElmer Inc., Quest Diagnostics Inc., R Biopharm AG, Siemens AG, Svar Life Science AB, Thermo Fisher Scientific Inc., and Werfenlife SA |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
